Trial Radar AI

Let's discuss and explore clinical trials with Syndax Pharmaceuticals as a lead sponsor or collaborator.

I can help you find nearby clinical trials and understand health conditions and treatments.
30 Clinical Trials
 
Phase
Phase 1
×
 
Study Title
Status
A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia NCT07283640
Not yet recruiting
Revumenib in Combination With 7+3 + Midostaurin in AML NCT06313437
Recruiting
A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib NCT06284486
Recruiting
A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias NCT06226571
Recruiting
Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia NCT06177067
Recruiting
Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors NCT05731947
Completed
Study of Radiolabeled Revumenib in Adults With Acute Leukemia NCT05406817
Completed
A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE) NCT05360160
Recruiting
A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia NCT05326516
Completed
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation (AUGMENT-101) NCT04065399
Recruiting
Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers NCT03924245
Terminated
A Study of Entinostat and FOLFOX in Subjects With Pancreatic Adenocarcinoma NCT03760614
Withdrawn
A Phase 1/2 Study to Evaluate Axatilimab in Participants With Active cGVHD NCT03604692
CompletedResults Posted
A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy (Breast49) NCT03473639
Completed
Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC NCT03361800
Terminated
A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors NCT03238027
Completed
A Study to Evaluate the Pharmacokinetics of Entinostat in Adult Subjects With Normal and Impaired Renal Function NCT03192111
Completed
A Study to Examine the Effects of Entinostat on Midazolam in Healthy Adult Subjects NCT03187015
Completed
Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma NCT03024437
TerminatedResults Posted
Study to Determine the Effect of the Timing of a Meal on the Pharmacokinetics of Entinostat NCT02922946
Completed
A Study to Examine the Effect of Omeprazole, Famotidine, and an Acidic Beverage on the Pharmacokinetics of Entinostat in Healthy Adult Subjects NCT02922933
Completed
Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer NCT02915523
CompletedResults Posted
Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors NCT02909452
Completed
Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors NCT02897778
Completed
Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer NCT02820961
Completed
Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In NCT02708680
CompletedResults Posted
Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC) NCT02437136
CompletedResults Posted
Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer (ENCORE110) NCT01594398
Completed
A Phase I, Multicenter, Open Label Study on the Effects of SNDX-275 on Expression of Biomarkers in Subjects With Newly Diagnosed Breast Cancer NCT00754312
Terminated
Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC NCT00602030
CompletedResults Posted